Silence Therapeutics signs collaboration with MiReven Pty Ltd to evaluate delivery of novel microRNA-based therapeutics

London, UK, August 22, 2012 – Silence Therapeutics plc (AIM: SLN) (“Silence”), a leading RNA interference (RNAi) therapeutics company, announces that it has signed an agreement with MiReven Pty Ltd (“MiReven”), to assess the delivery potential of Silence’s proprietary delivery systems with MiReven’s novel microRNA-based therapeutics. MiReven, an Australian-based microRNA company, is commercialising discoveries from the Western Australian Institute for Medical Research (WAIMR) on the anti-cancer potential of miR-7.

Read the full article

Avatar for cwraight
Comments are closed.